Aliases & Classifications for Vestibular Disease

MalaCards integrated aliases for Vestibular Disease:

Name: Vestibular Disease 12 15 17
Vestibular Diseases 45 74
Vertigo, Vestibular Disorder 12
Diseases of Inner Ear 74
Vestibular Disorder 56

Classifications:



External Ids:

Disease Ontology 12 DOID:3426
MeSH 45 D015837
SNOMED-CT 69 20425006
ICD10 34 H81 H81.9 H81.90

Summaries for Vestibular Disease

MalaCards based summary : Vestibular Disease, also known as vestibular diseases, is related to meniere disease and deafness, autosomal dominant 9, and has symptoms including vertigo and vertigo/dizziness. An important gene associated with Vestibular Disease is COCH (Cochlin), and among its related pathways/superpathways are Myometrial Relaxation and Contraction Pathways and Dopamine-DARPP32 Feedback onto cAMP Pathway. The drugs Histamine and Dimenhydrinate have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and eye, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Vestibular Disease

Diseases related to Vestibular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 83)
# Related Disease Score Top Affiliating Genes
1 meniere disease 31.5 AQP2 COCH FAM136A
2 deafness, autosomal dominant 9 30.5 COCH FAM136A
3 deafness, autosomal recessive 4, with enlarged vestibular aqueduct 30.4 COCH FOXI1 GJB2 GJB3 GJB6 KCNJ10
4 motion sickness 30.0 AVP FAM136A
5 congenital cytomegalovirus 29.7 GJB2 GJB6
6 benign paroxysmal positional nystagmus 29.4 CACNA1A OTOL1
7 sensorineural hearing loss 29.2 COCH GJB2 GJB3 GJB6 SLC26A4
8 superior semicircular canal dehiscence 10.4 COCH RTEL1
9 deafness, autosomal dominant 36 10.4 GJB2 SLC26A4
10 hypotrichosis-deafness syndrome 10.3 GJB2 GJB3
11 deafness, autosomal recessive 93 10.3 GJB2 GJB3
12 deafness, autosomal recessive 28 10.3 GJB2 GJB3
13 deafness, autosomal recessive 26 10.3 GJB2 SLC26A4
14 deafness, autosomal dominant 6 10.3 COCH GJB2 SLC26A4
15 deafness, autosomal dominant 13 10.3 COCH GJB2 SLC26A4
16 mental retardation, enteropathy, deafness, peripheral neuropathy, ichthyosis, and keratoderma 10.3 GJB2 GJB3
17 deafness, autosomal recessive 30 10.3 GJB2 SLC26A4
18 drug-induced hearing loss 10.2 GJB2 GJB3 SLC26A4
19 autosomal recessive nonsyndromic deafness 3 10.2 GJB2 SLC26A4
20 inappropriate adh syndrome 10.2 AQP2 AVP
21 deafness, autosomal dominant 24 10.2 GJB2 GJB6
22 deafness, autosomal recessive 67 10.2 GJB2 GJB3
23 autosomal recessive nonsyndromic deafness 10.2 GJB2 SLC26A4
24 knuckle pads, leukonychia, and sensorineural deafness 10.2 GJB2 GJB6
25 deafness, x-linked 2 10.2 GJB2 GJB6
26 dfnb1 10.1 GJB2 GJB6
27 vohwinkel syndrome 10.1 GJB2 GJB6
28 impaired renal function disease 10.1 AQP2 AVP
29 syndrome of inappropriate antidiuretic hormone 10.1 AQP2 AVP
30 diabetes insipidus, neurohypophyseal 10.1 AQP2 AVP
31 obstructive hydrocephalus 10.1 CRLF1 GJB6
32 plexopathy 10.1 AVP CRLF1
33 cogan syndrome 10.1 CRLF1 GJB2
34 deafness, autosomal dominant 2a 10.1 COCH GJB2 GJB6
35 deafness, autosomal recessive 23 10.1 GJB2 GJB6 SLC26A4
36 pathologic nystagmus 10.1
37 vestibulocochlear nerve disease 10.0 CACNA1A RTEL1
38 ear malformation 10.0 FOXI1 GJB2 KCNJ10 SLC26A4
39 vestibular neuronitis 10.0 CACNA1A RTEL1
40 kid syndrome 10.0 GJB2 GJB3 GJB6
41 pseudoainhum 10.0 GJB2 GJB3 GJB6
42 deafness, autosomal recessive 1a 10.0 GJB2 GJB3 GJB6
43 brain compression 10.0 AVP GJB6
44 knuckle pads 10.0 GJB2 GJB3 GJB6
45 erythrokeratodermia variabilis et progressiva 1 10.0 GJB2 GJB3 GJB6
46 clouston syndrome 10.0 GJB2 GJB3 GJB6
47 seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance 10.0 AQP2 AVP KCNJ10
48 sphenoid sinusitis 10.0 AVP GJB6
49 deafness, autosomal recessive 16 9.9 COCH GJB2 GJB6 SLC26A4
50 hodgkin's lymphoma, nodular sclerosis 9.9 GJB2 GJB3 GJB6 SLC26A4

Graphical network of the top 20 diseases related to Vestibular Disease:



Diseases related to Vestibular Disease

Symptoms & Phenotypes for Vestibular Disease

UMLS symptoms related to Vestibular Disease:


vertigo, vertigo/dizziness

MGI Mouse Phenotypes related to Vestibular Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.92 AQP2 AVP CACNA1A CRLF1 FOXI1 GJB6
2 homeostasis/metabolism MP:0005376 9.9 AQP2 AVP CACNA1A FOXI1 GJB2 GJB3
3 hearing/vestibular/ear MP:0005377 9.8 COCH FOXI1 GJB2 GJB6 KCNE3 KCNJ10
4 nervous system MP:0003631 9.65 AVP CACNA1A CRLF1 FOXI1 GJB2 GJB6
5 no phenotypic analysis MP:0003012 9.1 AVP CACNA1A GJB2 GJB3 GJB6 KCNE3

Drugs & Therapeutics for Vestibular Disease

Drugs for Vestibular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 143)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 51-45-6 774
2
Dimenhydrinate Approved Phase 4,Phase 3 523-87-5 441281
3
Betahistine Approved, Investigational Phase 4,Phase 2,Not Applicable 5638-76-6 2366
4
Caffeine Approved Phase 4 58-08-2 2519
5
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
6
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
7
Calcium Carbonate Approved, Investigational Phase 4 471-34-1
8
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
9
Tocopherol Approved, Investigational Phase 4 1406-66-2 14986
10
Glycerol Approved, Investigational Phase 4 56-81-5 753
11
Thymol Approved Phase 4 89-83-8 6989
12
Ethanol Approved Phase 4 64-17-5 702
13
Phenol Approved, Experimental Phase 4 108-95-2 996
14
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
15
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
16
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
17
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
18
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
19
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
20
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
21
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
22
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 1 7440-70-2 271
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
24
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
25
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
26 Tocotrienol Investigational Phase 4 6829-55-6
27
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
28
Histamine Phosphate Phase 4,Phase 3,Phase 2,Not Applicable 51-74-1 65513
29 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
31 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
32 Histamine H1 Antagonists Phase 4,Phase 3,Not Applicable
33 Antiemetics Phase 4,Phase 3,Not Applicable
34 Gastrointestinal Agents Phase 4,Phase 3,Not Applicable
35 Histamine Antagonists Phase 4,Phase 3,Not Applicable
36 Vasodilator Agents Phase 4,Phase 2,Phase 1,Not Applicable
37 Phosphodiesterase Inhibitors Phase 4,Not Applicable
38 Central Nervous System Stimulants Phase 4
39 Purinergic P1 Receptor Antagonists Phase 4
40 Dopamine Antagonists Phase 4
41 Dopamine D2 Receptor Antagonists Phase 4
42 Dopamine Agents Phase 4
43 Calciferol Phase 4
44 Vitamins Phase 4
45 Trace Elements Phase 4
46 Ergocalciferols Phase 4
47 Micronutrients Phase 4
48 Bone Density Conservation Agents Phase 4
49 Vitamin D2 Phase 4
50 Calcium Supplement Phase 4

Interventional clinical trials:

(show top 50) (show all 173)
# Name Status NCT ID Phase Drugs
1 Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients Unknown status NCT00132223 Phase 4 Contrast agent
2 Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Meniere's Disease and Having Undergone Vestibular Neurotomy Completed NCT00160238 Phase 4 Betahistine 24 mg bid (Betaserc)
3 Effect of Caffeine Intake in Vestibular Function Completed NCT02825199 Phase 4
4 Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo Completed NCT01890538 Phase 4 Administration of 100 mg dimenhydrinate intravenous;2 g piracetam intravenous
5 Comparison of Efficacy Dimenhydrinate and Metoclopramide in the Treatment of Nausea Due to Vertigo Completed NCT02253524 Phase 4 Dimenhydrinate;Metoclopramide
6 Efficacy of Vitamin D and Calcium Supplementation on the Prevention of Recurrences in BPPV Completed NCT02031692 Phase 4 400IU cholecalciferol and 500mg of elemental calcium as calcium carbonate
7 Effect of Stellate Ganglion Block on Meniere's Disease Completed NCT01574313 Phase 4 0.25mg, fludiazine;25mg cephadol@ (diphenidol);200mg kentons@ (tocopherol nicotinate).
8 Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal Completed NCT00765635 Phase 4 drops intilation (Taponoto ® );drops intilation (Otocerum®);drops intilation (Placebo)
9 Acute Unilateral Vestibulopathy and Corticosteroid Treatment Recruiting NCT02912182 Phase 4 Betamethasone;Placebo;Prednisolone
10 A Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation Withdrawn NCT00474409 Phase 4 Merislon
11 Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin Unknown status NCT02112578 Phase 3 Meclizine;Dimenhydrinate
12 Efficacy of Antiviral Medications in Controlling Vertigo Attacks of Patients With Meniere's Disease Unknown status NCT01729767 Phase 2, Phase 3 Acyclovir;Placebo
13 Conventional Versus Virtual Reality Based Vestibular Rehabilitation Completed NCT01442623 Phase 2, Phase 3
14 Study of Lamotrigine to Treat Ménière's Disease Completed NCT02158585 Phase 3 Lamotrigine;Placebo
15 The Treatment of Posterior Semicircular Canal Benign Paroxysmal Positional Vertigo Completed NCT02029508 Phase 3
16 Promethazine vs. Lorazepam for Treatment of Vertigo Completed NCT01827293 Phase 3 Promethazine;Lorazepam
17 Treatment of Geotropic Horizontal Canal Benign Paroxysmal Positional Vertigo Completed NCT01366430 Phase 3
18 Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo Completed NCT00810641 Phase 3
19 Canalith Repositioning Procedure for BPPV in Primary Care Completed NCT00182273 Phase 3
20 Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria Completed NCT00785135 Phase 3
21 Rizatriptan for Episodic Dizziness in Vestibular Migraine Recruiting NCT02447991 Phase 2, Phase 3 Rizatriptan;Placebo
22 Visual Feedback Goggle for Positional Vertigo Treatment Unknown status NCT00729885 Phase 1, Phase 2
23 Efficacy of Extended-release, Once Daily Tramadol for Post Operative Analgesia in Shoulder Arthroscopy Unknown status NCT02247648 Phase 2 tramadol;Placebo
24 Prednisone Treatment for Vestibular Neuronitis Completed NCT00271791 Phase 2 Prednisone;Prednisone
25 A Clinical Trial To Evaluate Efficacy And Safety Of Levophencynonate Hydrochloride In Patient With Vertigo Completed NCT02299804 Phase 2 Levophencynonate Hydrochloric;Placebo
26 Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo Completed NCT02046980 Phase 2
27 Effect of V0251 in Acute Vertigo Completed NCT01583738 Phase 2 V0251;placebo
28 Treatments for Benign Paroxysmal Positional Vertigo (BPPV) Completed NCT00000359 Phase 2
29 A Trial of Booklet Based Self Management of Dizziness Completed NCT00732797 Phase 2
30 Vestibular Therapy in Alzheimer's Disease Not yet recruiting NCT03799991 Phase 1, Phase 2
31 AM-125 in the Treatment of Acute Peripheral Vertigo Following Vestibular Schwannoma Resection Not yet recruiting NCT03908567 Phase 2 Intranasal Drug;Oral Tablet
32 4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine Withdrawn NCT03578354 Phase 2 4-aminopyridine;Atenolol
33 Use of a Vibrotactile Sensory Prosthesis in Patients With Postural Imbalance and Spatial Disorientation Unknown status NCT00146952 Phase 1
34 Head-Mounted Vibrotactile Prosthesis for Patients With Chronic Postural Instability Completed NCT00889824 Phase 1
35 Verapamil vs. Sertraline for Vestibular Migraine & Chronic Subjective Dizziness Completed NCT01669304 Phase 1 Verapamil;Sertraline
36 Physiotherapy in Vestibular Disorders Unknown status NCT02746770 Not Applicable
37 Game Based Vestibular Exercise for Home Rehabilitation Unknown status NCT02134444 Not Applicable
38 Vestibular and Multisensory Influence on Bodily and Spatial Representations Unknown status NCT02072460 Not Applicable
39 Simultaneous Recordings of Cervical and Ocular Vestibular-evoked Myogenic Potentials Unknown status NCT03049683
40 Biological Rhythms and Vestibular System Unknown status NCT01839409 Not Applicable
41 Neural Mechanisms Engaged in Control of Eye Movements Unknown status NCT00999934
42 The Liberatory Maneuver for the Treatment of Benign Paroxysmal Positional Vertigo (BPPV) Unknown status NCT01008124 Not Applicable
43 Evaluation of the Sensorial Preference Unknown status NCT01146249
44 Vestibular System in Migrainous Vertigo Patients Unknown status NCT00901953
45 Comorbidity Between Balance and Childhood Anxiety Unknown status NCT00599742 Not Applicable
46 Efficacy of Postural Restriction in Treating Benign Paroxysmal Positional Vertigo Unknown status NCT02475239 Not Applicable
47 Tailored Care for Somatoform Vertigo/Dizziness Unknown status NCT02320851 Not Applicable
48 Treatment of Posterior Canal Type of Benign Paroxysmal Positional Vertigo Unknown status NCT01822002 Not Applicable
49 The Head Impulse Test in the Screening of Vestibular Function Unknown status NCT01426932
50 Electrical Stimulation and Chemotherapy Induced Peripheral Neuropathy Unknown status NCT02088996 Not Applicable

Search NIH Clinical Center for Vestibular Disease

Cochrane evidence based reviews: vestibular diseases

Genetic Tests for Vestibular Disease

Anatomical Context for Vestibular Disease

MalaCards organs/tissues related to Vestibular Disease:

42
Testes, Brain, Eye, Thyroid, Pons, Skin

Publications for Vestibular Disease

Articles related to Vestibular Disease:

(show top 50) (show all 76)
# Title Authors Year
1
Risk of traffic accidents after onset of vestibular disease assessed with a surrogate marker. ( 30963255 )
2019
2
Tone-induced cervical and ocular vestibular-evoked myogenic potentials: comparing abnormalities in traumatic and non-traumatic vestibular disease. ( 30295212 )
2018
3
Genetic contribution to vestibular diseases. ( 29582143 )
2018
4
An unusual case of peripheral vestibular disease in a cat following ear cleaning. ( 28216690 )
2017
5
Treating peripheral vestibular disease-associated nausea. ( 28432250 )
2017
6
Health care utilization, prognosis and outcomes of vestibular disease in primary care settings: systematic review. ( 27083883 )
2016
7
Developing and Implementing Diagnostic Prediction Models for Vestibular Diseases in Primary Care. ( 27577483 )
2016
8
Congenital vestibular disease in captive Sumatran tigers (Panthera tigris ssp. sumatrae) in Australasia. ( 26403953 )
2015
9
Endoscopic findings of the external ear canal in a group of clinically normal horses and horses with head shaking or vestibular disease. ( 24693653 )
2014
10
What is your neurologic diagnosis? Vestibular disease. ( 24871057 )
2014
11
Diagnostic imaging of peripheral vestibular disease in a Chinese goose (Anser cygnoides). ( 24881151 )
2014
12
Proposed treatment for geriatric vestibular disease in dogs. ( 25103883 )
2014
13
Central vestibular disease in a blue and gold macaw (Ara ararauna) with cerebral infarction and hemorrhage. ( 25115042 )
2014
14
Influence of vestibular disease on psychological distress: a multicenter study. ( 23380760 )
2013
15
Diversity of head shaking nystagmus in peripheral vestibular disease. ( 22525213 )
2012
16
Vestibular disease: anatomy, physiology, and clinical signs. ( 22847320 )
2012
17
Vestibular disease: diseases causing vestibular signs. ( 22847321 )
2012
18
Modifications of muscle synergies and spinal maps due to absence of visual feedback in patients with unilateral vestibular disease. ( 23366708 )
2012
19
Patients' psychological well-being and resilient coping protect from secondary somatoform vertigo and dizziness (SVD) 1 year after vestibular disease. ( 20717689 )
2011
20
Selective atonal gene delivery improves balance function in a mouse model of vestibular disease. ( 21472006 )
2011
21
The reliability and response stability of dynamic testing of the vestibulo-ocular reflex in patients with vestibular disease. ( 22101298 )
2011
22
Clinical signs, magnetic resonance imaging findings and outcome in 77 cats with vestibular disease: a retrospective study. ( 19932040 )
2010
23
Vestibular disease in dogs and cats. ( 19942058 )
2010
24
Reliability, validity, and sensitivity to change of Turkish Activities-specific Balance Confidence Scale in patients with unilateral peripheral vestibular disease. ( 20183891 )
2010
25
Clinical romberg testing does not detect vestibular disease. ( 20502374 )
2010
26
New methods for diagnosis and treatment of vestibular diseases. ( 21173877 )
2010
27
Medical management of common peripheral vestibular diseases. ( 20827085 )
2010
28
Surgical management of common peripheral vestibular diseases. ( 20729736 )
2010
29
Different types of dizziness in patients with peripheral vestibular diseases--their prevalence and relation to migraine. ( 20380548 )
2010
30
Diabetic polyneuropathy may increase the handicap related to vestibular disease. ( 19427968 )
2009
31
What is your neurologic diagnosis? Vestibular disease secondary to brain neoplasm. ( 19284335 )
2009
32
Unilateral vestibular disease. ( 19412404 )
2009
33
Blood glucose and insulin levels in patients with peripheral vestibular disease. ( 19893939 )
2009
34
Depersonalisation/derealisation symptoms and updating orientation in patients with vestibular disease. ( 17578858 )
2008
35
Digital craniocorpography and peripheral vestibular diseases. ( 18616084 )
2008
36
The effect of vestibular rehabilitation supplemented by training of the breathing rhythm or proprioception exercises, in patients with chronic peripheral vestibular disease. ( 18219105 )
2007
37
Depersonalisation/derealisation symptoms in vestibular disease. ( 16464901 )
2006
38
Hypothyroid-associated central vestibular disease in 10 dogs: 1999-2005. ( 17186851 )
2006
39
Signs of neurologic dysfunction in dogs with central versus peripheral vestibular disease. ( 16117064 )
2005
40
Subjective assessment of visual verticality in follow-up of patients with acute vestibular disease. ( 12861870 )
2003
41
Vestibular disease and cognitive dysfunction: no evidence for a causal connection. ( 12973270 )
2003
42
Feline vestibular diseases--new developments. ( 12670436 )
2003
43
Visual and psychological aspects of vestibular disease. ( 11796943 )
2002
44
Is hyperventilation-induced nystagmus more common in retrocochlear vestibular disease than in end-organ vestibular disease? ( 12121015 )
2002
45
Head shaking nystagmus in the follow-up of patients with vestibular diseases. ( 11994119 )
2002
46
Paradoxical vestibular disease with trigeminal nerve-sheath tumor in a dog. ( 11525099 )
2001
47
Peripheral vestibular disease associated with cryptococcosis in three cats. ( 11716589 )
2000
48
Psychiatric symptoms and distress differ between patients with postherpetic neuralgia and peripheral vestibular disease. ( 10750630 )
2000
49
In vitro release kinetics of gentamycin from a sodium hyaluronate gel delivery system suitable for the treatment of peripheral vestibular disease. ( 10028414 )
1999
50
Vestibular disease in two horses: a case of mycotic otitis media and a case of temporohyoid osteoarthropathy. ( 10466833 )
1999

Variations for Vestibular Disease

Expression for Vestibular Disease

Search GEO for disease gene expression data for Vestibular Disease.

Pathways for Vestibular Disease

GO Terms for Vestibular Disease

Cellular components related to Vestibular Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gap junction GO:0005921 9.13 GJB2 GJB3 GJB6
2 connexin complex GO:0005922 8.8 GJB2 GJB3 GJB6

Biological processes related to Vestibular Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.55 AQP2 CACNA1A GJB2 GJB3 SLC26A4
2 regulation of ion transmembrane transport GO:0034765 9.54 CACNA1A KCNE3 KCNJ10
3 renal water homeostasis GO:0003091 9.43 AQP2 AVP
4 adult walking behavior GO:0007628 9.4 CACNA1A KCNJ10
5 water transport GO:0006833 9.32 AQP2 AVP
6 regulation of membrane potential GO:0042391 9.26 CACNA1A KCNJ10
7 cell communication GO:0007154 9.13 GJB2 GJB3 GJB6
8 sensory perception of sound GO:0007605 8.92 COCH GJB2 GJB6 SLC26A4

Molecular functions related to Vestibular Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gap junction channel activity GO:0005243 8.62 GJB2 GJB3

Sources for Vestibular Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....